Skip to content
logo with text
  • What we do
    • Scouting and Out-Licensing
    • Consulting to BD&L
    • Training
  • Current Projects
    • Topical Candidate for Eczema and Related Conditions
    • Custom Nanocomplex Formulation Opportunities
  • About Us
  • Contact
Menu
  • What we do
    • Scouting and Out-Licensing
    • Consulting to BD&L
    • Training
  • Current Projects
    • Topical Candidate for Eczema and Related Conditions
    • Custom Nanocomplex Formulation Opportunities
  • About Us
  • Contact

BioTrinity Panel Discussions

  • Post author:Carlos
  • Post published:April 21, 2011
  • Post category:Biotech/Conferences/Drug Delivery/Pharmaceutical/Venture Capital

We regret that we were unable to attend the panel discussions at BioTrinity last week. However, an excellent summary was posted on the PharmaPhorum web site. Of note: 1. Investment…

Continue ReadingBioTrinity Panel Discussions

Report on BioTrinity Partnering, April 12-14

  • Post author:Carlos
  • Post published:April 19, 2011
  • Post category:Biotech/Conferences

Last week, Lacerta Bio attended the annual BioTrinity Partnering and Investment Conference in Newbury, UK. This was our first time at this conference. So how was the conference? A few…

Continue ReadingReport on BioTrinity Partnering, April 12-14

Impressions from Natural Products ExpoWest 2011

  • Post author:Carlos
  • Post published:March 15, 2011
  • Post category:Conferences/Government

This weekend was spent attending the Natural Products ExpoWest convention in Anaheim on behalf of a few of our clients. This was our first time attending this conference. Aside from…

Continue ReadingImpressions from Natural Products ExpoWest 2011

Thoughts on JP Morgan Conference

  • Post author:Carlos
  • Post published:January 17, 2011
  • Post category:Biotech/Conferences/Emerging Markets/Pharmaceutical/Venture Capital

There is a lot of good commentary and analysis of last week's JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as…

Continue ReadingThoughts on JP Morgan Conference

Impressions from JP Morgan – Day One

  • Post author:Carlos
  • Post published:January 12, 2011
  • Post category:Biotech/Conferences/Drug Development/Venture Capital

In our meetings and informal discussions, there were three items we heard again and again: 1. Last year was a terrible fund raising year from a VC-backed company perspective. 2.…

Continue ReadingImpressions from JP Morgan – Day One

Goin’ to Morgan? So are we!

  • Post author:Carlos
  • Post published:December 22, 2010
  • Post category:Conferences

Like many of you, we are already scheduling meetings at the annual JP Morgan Healthcare Conference in San Francisco in January. This is an invitation-only event, but that doesn't stop…

Continue ReadingGoin’ to Morgan? So are we!
  • Go to the previous page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8

Recent Posts

  • GIGO: AI and Drug Candidate Valuation – Part V
  • The Platform Question: AI and Drug Candidate Valuation – Part IV
  • On Getting pAId: AI and Drug Candidate Valuation – Part III
  • Children And Crayons: AI and Drug Candidate Valuation – Part II
  • Clowns on a Stage

Archives

  • March 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • June 2025
  • December 2024
  • October 2024
  • September 2024
  • April 2024
  • May 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • June 2022
  • March 2022
  • June 2021
  • February 2021
  • December 2020
  • September 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • May 2014
  • April 2014
  • February 2014
  • January 2014
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010

Categories

  • Artificial Intelligence
  • BD&L
  • Biosimilars
  • Biotech
  • Business Development/Licensing
  • China
  • Conferences
  • COVID-19
  • CRO
  • Diagnostics
  • Digital Health
  • Digital Medicine
  • Downsizing
  • Drug Delivery
  • Drug Development
  • Drug Discovery
  • Due Diligence
  • Emerging Markets
  • Entrepreneurship
  • Europe
  • Financing
  • Generics
  • Government
  • India
  • Marketing
  • Mergers & Acquisitions
  • Offshoring
  • Outsourcing
  • Pharmaceutical
  • Planning
  • Pricing
  • Reimbursement
  • Social Media
  • Tech Transfer
  • Uncategorized
  • Venture Capital

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Get in touch

To contact us, please email us at mail: info@lacertabio.com to schedule your free consultation, or call tele:+1 (845) 293-3343.